| Clinical Neurology | Lifetime | 32 | GB 7 | 99.88 |
| Neuroscience of Neurology | Lifetime | 63 | GB 7 | 99.48 |
| Cellular and Molecular Neuroscience | Lifetime | 373 | GB 41 | 98.65 |
| Rheumatology | Lifetime | 602 | GB 59 | 97.13 |
| Psychiatry and Mental health | Lifetime | 805 | GB 102 | 96.57 |
| Clinical Neurology | 2021-2025 | 56 | GB 12 | 98.83 |
| Cellular and Molecular Neuroscience | 2021-2025 | 70 | GB 4 | 94.73 |
| Botulinum Toxin and Related Neurological Disorders | Lifetime | 13 | GB 4 | 99.84 |
| Neuromodulation and Treatments for Neurological Disorders | Lifetime | 17 | GB 5 | 99.86 |
| Genetic Neurodegenerative Diseases | Lifetime | 19 | GB 5 | 99.78 |
| Neurological and metabolic disorders | Lifetime | 9 | GB 2 | 99.66 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 12 | GB 5 | 99.55 |
| Parkinson's Disease Mechanisms and Treatments | Lifetime | 64 | GB 11 | 99.73 |
| Neurological diseases and metabolism | Lifetime | 31 | GB 9 | 99.50 |
| Autoimmune Neurological Disorders and Treatments | Lifetime | 32 | GB 4 | 98.60 |
| Transcranial Magnetic Stimulation Studies | Lifetime | 97 | GB 7 | 98.92 |
| Metabolism and Genetic Disorders | Lifetime | 509 | GB 38 | 98.32 |
| Psychosomatic Disorders and Their Treatments | Lifetime | 187 | GB 49 | 98.42 |
| RNA regulation and disease | Lifetime | 360 | GB 28 | 96.84 |
| Epilepsy research and treatment | Lifetime | 626 | GB 46 | 97.44 |
| Hereditary Neurological Disorders | Lifetime | 200 | GB 23 | 96.48 |
| Genetics and Neurodevelopmental Disorders | Lifetime | 839 | GB 96 | 96.35 |
| Porphyrin Metabolism and Disorders | Lifetime | 324 | GB 27 | 95.39 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 612 | GB 62 | 95.06 |
| Parkinson's Disease and Spinal Disorders | Lifetime | 240 | GB 22 | 90.15 |
| Neurology and Historical Studies | Lifetime | 348 | GB 55 | 88.65 |
| Cerebrovascular and genetic disorders | Lifetime | 580 | GB 61 | 82.22 |
| Restless Legs Syndrome Research | Lifetime | 933 | GB 42 | 80.36 |
| Genetic Neurodegenerative Diseases | 2021-2025 | 26 | GB 4 | 98.02 |
| Neuromodulation and Treatments for Neurological Disorders | 2021-2025 | 47 | GB 6 | 98.69 |
| Botulinum Toxin and Related Neurological Disorders | 2021-2025 | 68 | GB 5 | 96.52 |
| Parkinson's Disease Mechanisms and Treatments | 2021-2025 | 164 | GB 14 | 97.70 |
| Genetics and Neurodevelopmental Disorders | 2021-2025 | 261 | GB 23 | 92.52 |
| Autoimmune Neurological Disorders and Treatments | 2021-2025 | 92 | GB 5 | 91.89 |
| Neurological and metabolic disorders | 2021-2025 | 77 | GB 2 | 82.24 |
| Glycogen Storage Diseases and Myoclonus | 2021-2025 | 134 | GB 11 | 83.47 |
| Cellular transport and secretion | 2021-2025 | 507 | GB 37 | 78.85 |
| Hereditary Neurological Disorders | 2021-2025 | 302 | GB 25 | 77.06 |
| Neurological diseases and metabolism | 2021-2025 | 412 | GB 43 | 73.40 |
| Restless Legs Syndrome Research | 2021-2025 | 684 | GB 26 | 50.20 |